PTPA and Alzheimer disease: Moreover, in vivo experiments revealed the potential of isobavachalcone in reducing tau protein phosphorylation at four sites, T231, S396, S404, and S422, associated with tauopathies impairments, by regulating GSK‐3β and PP2A.[180] In another study, isobavachalcone was administered to 3×Tg‐AD mice, which resulted in improved memory, recognition, and anxiety, along with a reduction in the accumulation of Aβ oligomers and tau hyperphosphorylation.